Cannabis company Cookies expands in Europe in partnership with InterCure: 'focus on new territories'

Cannabis company Cookies expands in Europe in partnership with InterCure: 'focus on new territories'
Brands
Pot
Cookies, a San Francisco-based cannabis company, is expanding to Europe. | File Photo

Cookies, a San Francisco-based company that makes cannabis products, is expanding into Europe in a partnership with InterCure, a news release said.

"As we focus on new territories, it's vital our customers continue to count on the quality Cookies is known for, which is a value we share with our partners at InterCure,” Parker Berling, president of Cookies, said in a statement. “We  look forward to reaching audiences in Austria and the United Kingdom and establishing Cookies as a mainstay in each community."

InterCure is already distributing Cookies-branded products in Israel through its Cookies national medical cannabis pharmacy chain, the news release said. InterCure specializes in making sure it meets the standards of good manufacturing practice (GMP) whether producing, manufacturing or distributing.

"Cookies is one of the most internationally recognized brands in cannabis, and after our mutual success in Israel, it's only obvious we further our expansion to Europe, providing the highest quality grade cannabis products," Alexander Rabinovitch, CEO of InterCure, said in a statement.

Cookies was founded in 2010 by "Billboard-charting rapper and entrepreneur Berner and Bay Area breeder and cultivator Jai," the news release said. After opening its first store in LA in 2018, Cookies continued on a path of growth with 40 retail sites in 17 markets across four countries.

It is "the most globally recognized cannabis company in the world," the release said.

"Cookies values the power of the plant and focuses on creating game-changing genetics," it said. "The company offers a collection of over 70 proprietary cannabis strains and more than 2,000 products"

According to the release, the company "actively works to enrich communities disproportionately impacted by the War on Drugs through advocacy and social equity initiatives."